Source:http://linkedlifedata.com/resource/pubmed/id/15661546
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2005-1-21
|
| pubmed:abstractText |
There are limited data that define the role of chemotherapy in the treatment of high-grade spindle cell sarcomas of bone, other than osteosarcoma or malignant fibrous histiocytoma (MFH-B). This prospective study evaluates the effect of doxorubicin and cisplatin on these tumours. Thirty-seven patients, age 65 years, with spindle cell sarcoma of bone, except osteosarcoma or MFH-B, were included. Chemotherapy consisted of doxorubicin and cisplatin every 3 weeks for six cycles. Resection was performed after three cycles. In 15 patients with metastases, response assessment showed three complete responses (CR), four stable disease (SD), five progression; three were not evaluable. Median time to progression was 30 months (95% Confidence Interval (CI), 8-51 months) for the operable non-metastatic patients; median survival 41 months (95% CI, 16-82 months). Median time to progression in the metastatic group was 10 months (95% CI, 0-18 months) and median survival was 14 months (95% CI, 4-45 months). This study suggests a limited role for doxorubicin and cisplatin in metastatic high-grade spindle cell sarcoma of bone, other than osteosarcoma or MFH-B cases.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0959-8049
|
| pubmed:author |
pubmed-author:BramwellV H CVH,
pubmed-author:CannonSS,
pubmed-author:CraftA WAW,
pubmed-author:European Osteosarcoma Intergroup,
pubmed-author:GlabbekeM vM,
pubmed-author:HogendoornP C WPC,
pubmed-author:KirkpatrickAA,
pubmed-author:NooijM AMA,
pubmed-author:PringleJJ,
pubmed-author:TaminiauA TAT,
pubmed-author:UscinskaB MBM,
pubmed-author:WeedenSS,
pubmed-author:WhelanJJ
|
| pubmed:issnType |
Print
|
| pubmed:volume |
41
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
225-30
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:15661546-Adolescent,
pubmed-meshheading:15661546-Adult,
pubmed-meshheading:15661546-Aged,
pubmed-meshheading:15661546-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15661546-Bone Neoplasms,
pubmed-meshheading:15661546-Cisplatin,
pubmed-meshheading:15661546-Combined Modality Therapy,
pubmed-meshheading:15661546-Disease Progression,
pubmed-meshheading:15661546-Doxorubicin,
pubmed-meshheading:15661546-Female,
pubmed-meshheading:15661546-Humans,
pubmed-meshheading:15661546-Infusions, Intravenous,
pubmed-meshheading:15661546-Lymphatic Metastasis,
pubmed-meshheading:15661546-Male,
pubmed-meshheading:15661546-Middle Aged,
pubmed-meshheading:15661546-Prospective Studies,
pubmed-meshheading:15661546-Rare Diseases,
pubmed-meshheading:15661546-Sarcoma,
pubmed-meshheading:15661546-Survival Analysis,
pubmed-meshheading:15661546-Treatment Outcome
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study.
|
| pubmed:affiliation |
Department of Clinical Oncology K1-P, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, The Netherlands. M.A.Nooji@lumc.nl
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|